Veracyte

Veracyte is a pioneering genomic diagnostics company. The Company is developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy. 

Veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards.

Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
2008
Size (employees)
216 (est)
Veracyte was founded in 2008 and is headquartered in South San Francisco, US

Key People/Management at Veracyte

Bonnie Anderson

Bonnie Anderson

Co-Founder & CEO
Shelly D. Guyer

Shelly D. Guyer

CFO
Richard Lanman

Richard Lanman

Chief Medical Officer
Giulia C. Kennedy

Giulia C. Kennedy

Chief Scientific Officer
Chris Hall

Chris Hall

Chief Commercial Officer
Robert Monroe

Robert Monroe

VP, Laboratory Operations & Medical Director

Veracyte Office Locations

Veracyte has offices in South San Francisco and Austin
South San Francisco, US (HQ)
300 6000 Shoreline Ct
Austin, US
100 12357 Riata Trace Pkwy

Veracyte Financials and Metrics

Veracyte Financials

Veracyte's revenue was reported to be $16.4 m in Q1, 2017
USD

Revenue (Q1, 2017)

16.4 m

Gross profit (Q1, 2017)

10.1 m

Gross profit margin (Q1, 2017), %

62%

Net income (Q1, 2017)

(8.2 m)

EBIT (Q1, 2017)

(7.5 m)

Market capitalization (20-Oct-2017)

315 m

Cash (31-Dec-2016)

59.2 m

EV

280.7 m
Veracyte's current market capitalization is $315 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

21.9 m38.2 m49.5 m65.1 m

Revenue growth, %

75%30%31%

Cost of goods sold

12.6 m16.6 m21.5 m25.5 m

Gross profit

9.3 m21.6 m28 m39.6 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

11.2 m11.9 m12.3 m13.6 m14.7 m18.6 m16.4 m

Cost of goods sold

4.6 m5.1 m5.6 m6.3 m6.3 m6.4 m6.3 m

Gross profit

6.7 m6.8 m6.7 m7.3 m8.4 m12.2 m10.1 m

Gross profit Margin, %

59%57%54%54%57%66%62%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

71.2 m35 m39.1 m59.2 m

Accounts Receivable

1.1 m3.1 m3.5 m8.8 m

Inventories

1.5 m1.2 m1.5 m2.1 m

Current Assets

76.4 m43.3 m47.9 m73.6 m
USDQ1, 2015Q2, 2015

Cash

25.8 m51 m

Current Assets

33.7 m60.7 m

PP&E

4.1 m4.2 m

Goodwill

1.1 m1.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(25.6 m)(29.4 m)(33.7 m)(31.4 m)

Depreciation and Amortization

999 k1.2 m2.3 m3.5 m

Accounts Receivable

(683 k)(2 m)(558 k)(5.3 m)

Accounts Payable

3.3 m1.9 m(3.5 m)(1.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7.6 m)(9.1 m)(8.9 m)(10.1 m)(11.2 m)(5.6 m)(8.2 m)

Accounts Receivable

3.4 m6.3 m9.1 m

Accounts Payable

8.5 m8.6 m6.9 m2.7 m6.6 m4.3 m2.7 m3.1 m2.6 m
USDY, 2017

EV/EBIT

-37.3 x

Revenue/Employee

76.1 k
Show all financial metrics

Veracyte Operating Metrics

FY, 2016

Products

3

Patents Issued

13

Facilities

2
Show all operating metrics

Veracyte Market Value History

Traffic Overview of Veracyte

Veracyte Online and Social Media Presence

Veracyte Company Life and Culture

You may also be interested in